Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
NCT ID: NCT00844649
Last Updated: 2019-11-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
861 participants
INTERVENTIONAL
2009-03-01
2013-04-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
NCT00398086
Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
NCT01964534
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
NCT06789679
Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
NCT02017015
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
NCT02993731
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Albumin-bound paclitaxel (ABI-007)/Gemcitabine
ABI-007 125 mg/m2 administered in combination with gemcitabine 1000 mg/m2 weekly for 3 weeks followed by one week of rest.
Albumin-bound paclitaxel (ABI-007)
ABI-007 125 mg/m\^2 administered by intravenous infusion
Gemcitabine
Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
Gemcitabine
Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks followed by a week of rest (Cycle 2 onward).
Gemcitabine
Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Albumin-bound paclitaxel (ABI-007)
ABI-007 125 mg/m\^2 administered by intravenous infusion
Gemcitabine
Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Participant has definitive histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. The definitive diagnosis of metastatic pancreatic adenocarcinoma will be made by integrating the histopathological data within the context of the clinical and radiographic data. Participants with islet cell neoplasms are excluded.
2. Initial diagnosis of metastatic disease must have occurred ≤6 weeks prior to randomization in the study.
3. Patient has one or more metastatic tumors measurable by Computed Tomography (CT) scan or Magnetic resonance imaging (MRI), if patient is allergic to CT contrast media).
4. Male or non-pregnant and non-lactating female, and ≥ 18 years of age. If a female patient is of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test Beta-Human Chorionic Gonadotropin (β-hCG) documented 72 hours prior to the first administration of study drug.
If sexually active, the patient must agree to use contraception considered adequate and appropriate by the Investigator during the period of administration of study drug. In addition, male and female patients must utilize contraception after the end of treatment as recommended in the product's Summary of Product Characteristics or Prescribing Information provided in the study manual.
5. Patients must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease. Prior treatment with 5-Fluorouracil (5-FU) or gemcitabine administered as a radiation sensitizer in the adjuvant setting is allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present. Patients having received cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting are not eligible for this study.
6. Patient has adequate biological parameters as demonstrated by the following blood counts at Baseline (obtained ≤14 days prior to randomization):
Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L; Platelet count ≥ 100,000/mm\^3 (100 × 10\^9/L); Hemoglobin (Hgb) ≥ 9 g/dL.
7. Patient has the following blood chemistry levels at Baseline (obtained ≤14 days prior to randomization):
Aspartate Transaminase (AST), Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Transaminase ( ALT) Serum Glutamic-Pyruvic Transaminase (SGPT) ≤ 2.5 × upper limit of normal range (ULN), unless liver metastases are clearly present, then ≤ 5 × ULN is allowed Total bilirubin ≤ ULN Serum creatinine within normal limits or calculated clearance ≥ 60 mL/min/1.73 m\^2 for patients with serum creatinine levels above or below the institutional normal value. If using creatinine clearance, actual body weight should be used for calculating creatinine clearance (e.g., using the Cockroft-Gault formula). For patients with a Body Mass Index (BMI) \>30 kg/m\^2, lean body weight should be used instead.
8. Patient has acceptable coagulation studies (obtained ≤14 days prior to randomization) as demonstrated by prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits (± 15%).
9. Patient has no clinically significant abnormalities in urinalysis results (obtained ≤14 days prior to randomization).
10. Patient has a Karnofsky performance status (KPS) ≥ 70. Two observers will be required to assess KPS. If discrepant, the one with the lowest assessment will be considered true.
11. Patients should be asymptomatic for jaundice prior to Day 1. Significant or symptomatic amounts of ascites should be drained prior to Day 1. Pain symptoms should be stable and should not require modifications in analgesic management prior to Day 1.
12. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form (ICF) prior to participation in any study-related activities.
Exclusion Criteria
1. Patient has known brain metastases, unless previously treated and well-controlled for at least 3 months (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart).
2. Patient has only locally advanced disease.
3. Patient has experienced a ≥10% decrease in KPS between baseline visit and within 72 hours prior to randomization.
4. Patient has a ≥20% decrease in serum albumin level between baseline visit and within 72 hours prior to randomization.
5. History of malignancy in the last 5 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.
6. Patient uses Coumadin.
7. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
8. Patient has known historical or active infection with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C.
9. Patient has undergone major surgery, other than diagnostic surgery (i.e.--surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.
10. Patient has a history of allergy or hypersensitivity to any of the study drugs or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the product or comparator Summary of Product Characteristics (SmPC) or Prescribing Information.
11. History of connective tissue disorders (e.g., lupus, scleroderma, arteritis nodosa).
12. Patients with a history of interstitial lung disease.
13. History of chronic leukemias (e.g., chronic lymphocytic leukemia).
14. Patients with high cardiovascular risk, including, but not limited to, recent coronary stenting or myocardial infarction in the past year.
15. History of Peripheral Artery Disease (e.g,. claudication, Leo Buerger's disease).
16. Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity.
17. Patient is enrolled in any other clinical protocol or investigational trial.
18. Patient is unwilling or unable to comply with study procedures, or is planning to take vacation for 7 or more consecutive days during the course of the study.
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Von Hoff, MD
Role: PRINCIPAL_INVESTIGATOR
Scottsdale Clinical Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAB Comprenhensive Cancer Center at University of Alabama
Birmingham, Alabama, United States
Clearview Cancer Institute Oncology Specialities, P.C.
Huntsville, Alabama, United States
TGEN Clinical Research Services at Scottsdale Healthcare
Scottsdale, Arizona, United States
Mayo Clinic-Scottsdale
Scottsdale, Arizona, United States
Northern Arizona Hematology and Oncology Associates-AOA
Sedona, Arizona, United States
Arizona Cancer Center, University of Arizona
Tucson, Arizona, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
Tower Cancer Research Foundation
Beverly Hills, California, United States
City of Hope
Duarte, California, United States
Pacific Shores Medical Group
Long Beach, California, United States
UCLA
Los Angeles, California, United States
Desert Hematology Oncology Medical Group, Inc.
Rancho Mirage, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
University Cancer Institute, LLC
Boynton Beach, Florida, United States
Collaborative Research Group
Boynton Beach, Florida, United States
FL Cancer Specialist
Fort Myers, Florida, United States
Lakeland Regional Cancer Center
Lakeland, Florida, United States
Ocala Oncology Center
Ocala, Florida, United States
Florida Hospital Cancer Institute
Orlando, Florida, United States
Lake County Oncology and Hematology
Tavares, Florida, United States
Phoebe Putney Cancer Center
Albany, Georgia, United States
Northeast Georgia Cancer Care, LLC
Athens, Georgia, United States
Piedmont Hospital Research Institute
Atlanta, Georgia, United States
Georgia Cancer Specialists
Atlanta, Georgia, United States
Atlanta Cancer Care
Atlanta, Georgia, United States
Cancer Care & Hemaotology Specialists of Chicagoland
Arlington Heights, Illinois, United States
NorthShore University HealthSystem
Evanston, Illinois, United States
Cancer Care & Hematology Specialists of Chicagoland
Niles, Illinois, United States
Illinois Cancer Care
Peoria, Illinois, United States
Orchard Research
Skokie, Illinois, United States
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
Hutchinson Clinic, PA
Hutchinson, Kansas, United States
Owsley Brown Frazier Cancer Center
Louisville, Kentucky, United States
Hematology Oncology Clinic
Baton Rouge, Louisiana, United States
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
Central Maine Medical Center
Lewiston, Maine, United States
Mercy Hospital Portland, ME
Portland, Maine, United States
Maine Center for Cancer Medicine
Scarborough, Maine, United States
Sidney Kimmel Comphrensive Cancer Center, John Hopkins University
Baltimore, Maryland, United States
Center for Cancer & Blood Disorders
Bethesda, Maryland, United States
Lahey Clinic
Burlington, Massachusetts, United States
Cancer Center of Excellence/University of MA Medical School
Worcester, Massachusetts, United States
St. Mary's/ Duluth Clinic
Duluth, Minnesota, United States
Virginia Piper Cancer Institute
Minneapolis, Minnesota, United States
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota, United States
St. John's Medical Research Institute
Springfield, Missouri, United States
Saint Louis University
St Louis, Missouri, United States
The Center for Cancer and Hematologic Disease
Cherry Hill, New Jersey, United States
Hem Onc Associates-NM
Albuquerque, New Mexico, United States
University of New Mexico
Albuquerque, New Mexico, United States
New York Oncology Hematology PC
Albany, New York, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Arena Oncology Associates, PC
Lake Success, New York, United States
SUNY Upstate Medical University
Syracuse, New York, United States
Piedmont Hematology Oncology
Winston-Salem, North Carolina, United States
Oncology Hematology Care
Cincinnati, Ohio, United States
Mid Ohio Oncology/Hematology Inc
Columbus, Ohio, United States
Kettering Medical Center
Kettering, Ohio, United States
Signal Point Clinical Research Center, LLC
Middletown, Ohio, United States
Cancer Centers of SW OK
Lawton, Oklahoma, United States
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, United States
Mercy Physicians of Oklahoma
Oklahoma City, Oklahoma, United States
Cancer Care Associates- Tulsa
Tulsa, Oklahoma, United States
St. Mary Medical Center Hem-Onc Group, PC
Langhorne, Pennsylvania, United States
University of Pittsburg Medical Center
Pittsburgh, Pennsylvania, United States
South Carolina Oncology Associates
Columbia, South Carolina, United States
Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States
Tennessee Oncology
Nashville, Tennessee, United States
Medical City Dallas-US Oncology
Dallas, Texas, United States
Texas Oncology, PA
Dallas, Texas, United States
Texas Oncology, PA/ Methodist Charlton Cancer Center
Dallas, Texas, United States
Texas Oncology Laboratories
Fort Worth, Texas, United States
The Center for Cancer and Blood Disorders
Fort Worth, Texas, United States
The University of Texas Medical School at Houston
Houston, Texas, United States
Texas Oncology- Plano East
Plano, Texas, United States
Texas Oncology, PA
Round Rock, Texas, United States
Texas Oncology-Round Rock
Round Rock, Texas, United States
South Texas Oncology and Hematology, P.A
San Antonio, Texas, United States
Texas Oncology, PA
Wichita Falls, Texas, United States
Utah Cancer Specialists
Salt Lake City, Utah, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Fairfax-Northern Virginia Hematology-Oncology, P.C.
Fairfax, Virginia, United States
Virginia Cancer Specialist, PC
Fairfax, Virginia, United States
Virginia Cancer Institute
Richmond, Virginia, United States
Virginia Commonwealth University
Richmond, Virginia, United States
Swedish Health Services
Seattle, Washington, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Evergreen Hematology & Oncology
Spokane, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Bankstown-Lidcombe Hospital
Bankstown, New South Wales, Australia
Macarthur Cancer Therapy Center
Campbelltown, New South Wales, Australia
Concord Hospital
Concord, New South Wales, Australia
St. Vincent's Hospital
Darlinghurst, New South Wales, Australia
Prince of Wales Hospital
Randwick, New South Wales, Australia
Newcastle Hospital
Waratah, New South Wales, Australia
Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Haemotology & Oncology Australasia (HOCA)
Milton, Queensland, Australia
Haematology Oncology Clinics of Australasia-Gold Coast
Milton, Queensland, Australia
Adelaide Cancer Centre (T/A Ashford Cancer Ctr)
Ashford, South Australia, Australia
Flinders Medical Center
Bedford Park, South Australia, Australia
Calvary North Adelaide Hospital
North Adelaide, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Medical Oncology Unit, Bendigo Health
Bendigo, Victoria, Australia
Monash Medical Centre
East Bentleigh, Victoria, Australia
Western Hospital
Footscray, Victoria, Australia
Peninsula Oncology Centre
Frankston, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Border Medical Oncology
Wodonga, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Perth, Western Australia, Australia
Krankenhaus der Barmherzigen Schwestern Linz
Linz, , Austria
Landesklinikum St. Pölten
Sankt Pölten, , Austria
Medizinische Universität Wien
Vienna, , Austria
Klinikum Wels-Grieskirchen GmbH
Wels, , Austria
Imelda VZW , Gastro-Enterology
Bonheiden, , Belgium
Hôpital Erasme, Gastro-Enterology
Brussels, , Belgium
AZ Groeninge - Campus Sint-Niklaas
Kortrijk, , Belgium
H.-Hartziekenhuis Roeselare-Menen vzw
Roeselare, , Belgium
Tom Baker Cancer Centre
Calgary, Alberta, Canada
BC Cancer Agency-Vancouver
Vancouver, British Columbia, Canada
The Royal Victoria Hospital-Barrie
Barrie, Ontario, Canada
Hopital du Sacre-Coeur
Montreal, Quebec, Canada
Centre Hospitalier de L'Universite de Montreal St-Luc
Montreal, , Canada
Princess Margaret Hospital
Ontario, , Canada
Hotel-Dieu de Quebec
Québec, , Canada
Centre Regional de lutte contre le cancer Paul Papin
Angers, , France
Hôpital Saint Antoine
Paris, , France
Hôpital Beaujon
Paris, , France
Kliniken Essen-Mitte
Essen, , Germany
Klinikum Freising
Freising, , Germany
Praxis für Innere Medizin, Dr. Oettle Helmut
Friedrichshafen, , Germany
LMU Klinikum der Universität
Munich, , Germany
Klinikum Oldenburg
Oldenburg, , Germany
Universitätsklinikum Würzburg
Würzburg, , Germany
I.R.C.C.S. "Giovanni Paolo II" - Istituto Oncologico
Bari, , Italy
E. O. Ospedali Galliera, Struttura Complessa Oncologia Medica
Genova, , Italy
Nazionale per la Ricerca sul Cancro
Genova, , Italy
Fondazione Centro San Raffaele del Monte Tabor
Milan, , Italy
Oncologia Medica Falck
Milan, , Italy
Istituto Oncologico Veneto
Padua, , Italy
IRCCS Policlinico San Matteo
Pavia, , Italy
Azienda Ospedaliero universitaria Pisana
Pisa, , Italy
Arcispedale Santa Maria Nuova, Unità Operativa di Oncologia Medica
Reggio Emilia, , Italy
Arcispedale Santa Maria Nuova
Reggio Emilia, , Italy
Istituto Nazionale Tumori "Regina Elena"
Roma, , Italy
Istituto Clinico Humanitas
Rozzano, , Italy
Ospedale Casa Sollievo della Sofferenza IRCCS
San Giovanni Rotondo, Foggia, , Italy
Azienda Ospedaliera Universitaria Integrata di Verona
Verona, , Italy
Med Radiological Centre of the Russian Academy of Med Sciences
Obninsk, Kaluga Oblast, Russia
Tatarstan Republican Onc Ctr
Kazan', Tatarstan Republic, Russia
Altai Territorial Oncological Center
Barnaul, , Russia
Chelyabinsk Regional Onc Ctr
Chelyabinsk, , Russia
Ivanovo Regional Oncology Center
Ivanovo, , Russia
Regional Oncological Center # 2
Magnitogorsk, , Russia
Moscow City Clinical Hosp #57 Chemotherapy Dept
Moscow, , Russia
Blokhin Cancer Research Center
Moscow, , Russia
Russian Res Ctr of Radiology under the Fed Agency for Hi-Tech Med Care
Moscow, , Russia
Russian Research Ctr of Surgery n.a. B.V. Petrovskiy under the Russian Academy of Med Sciences
Moscow, , Russia
Central Clinical Hosp of the President of the Russian Federation
Moscow, , Russia
Semashko Central Hosp #2
Moscow, , Russia
Moscow Municipal Onc Hosp #62
Moscow Region, , Russia
Omsk Regional Onc Ctr
Omsk, , Russia
Orenburg Regional Onc Ctr
Orenburg, , Russia
Pyatigorsk Affiliate of Stavropol Regional Onc Ctr
Pyatigorsk, , Russia
Clinical Hosp # 122 n.a. L.G. Sokolov
Saint Petersburg, , Russia
Leningrad Regional Clinical Hosp
Saint Petersburg, , Russia
St. Petersburg State Med Academy n.a.Mechnikov
Saint Petersburg, , Russia
Russian Research Ctr for Radiology and Surgical Technologies
Saint Petersburg, , Russia
St. Petersburg City Onc Ctr
Saint Petersburg, , Russia
Tula Regional Oncology Center
Tula, , Russia
Bashkortostan Republican Onc Ctr
Ufa, , Russia
Yaroslavl Regional Onc Ctr
Yaroslavl, , Russia
Hospital Vall D´Hebron
Barcelona, , Spain
Hospital Clinic i Provincial
Barcelona, , Spain
Hospital Universitario Reina Sofia
Córdoba, , Spain
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Hospital 12 de Octubre
Madrid, , Spain
Centro Integral Oncológico Clara Campal
Madrid, , Spain
Hospital Virgen del Rocio
Seville, , Spain
Dnepropetrovsk City Hosp #4
Dnipro, UK, Ukraine
Donetsk Regional Antitumor Ctr
Donetsk, UK, Ukraine
Kirovohrad Regional Oncology Center, Department of Chemotherapy
Kirovohrad, UK, Ukraine
National Institute of Cancer, Department of Tumors of Abdominal Cavity and Retroperitoneum
Kyiv, UK, Ukraine
Kyiv City Clinical Hospital #10, Center for Hepatic, Bile Duct and Pancreatic Surgery
Kyiv, UK, Ukraine
Volyn Regional Oncology Center Department of Oncochemotherapy
Lutsk, UK, Ukraine
Lviv Regional Diagnostics and Treatment and Diagnostics Onc Ctr
Lviv, UK, Ukraine
O.F. Herbachevskyi Regional Clinical Hospital, Surgery Center
Zhytomyr, UK, Ukraine
Kharkov Regional Onc Ctr
Kharkiv, , Ukraine
Kherson Regional Onc Ctr
Kherson, , Ukraine
Odessa Regional Onc Ctr
Odesa, , Ukraine
Zaporizhia Medical Academy of Postgraduate Education
Zaporizhia, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, Romano A, Ferrara S, Von Hoff DD. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015 Feb;20(2):143-50. doi: 10.1634/theoncologist.2014-0394. Epub 2015 Jan 12.
Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016 Jul 12;115(2):188-94. doi: 10.1038/bjc.2016.185. Epub 2016 Jun 28.
Tehfe M, Dowden S, Kennecke H, El-Maraghi R, Lesperance B, Couture F, Letourneau R, Liu H, Romano A. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Adv Ther. 2016 May;33(5):747-59. doi: 10.1007/s12325-016-0327-4. Epub 2016 Apr 16.
Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A, Von Hoff DD. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016 Jun;7(3):469-78. doi: 10.21037/jgo.2016.01.03.
Vogel A, Rommler-Zehrer J, Li JS, McGovern D, Romano A, Stahl M. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer. 2016 Oct 21;16(1):817. doi: 10.1186/s12885-016-2798-8.
Kunzmann V, Ramanathan RK, Goldstein D, Liu H, Ferrara S, Lu B, Renschler MF, Von Hoff DD. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Pancreas. 2017 Feb;46(2):203-208. doi: 10.1097/MPA.0000000000000742.
Tabernero J, Kunzmann V, Scheithauer W, Reni M, Shiansong Li J, Ferrara S, Djazouli K. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. Onco Targets Ther. 2017 Feb 2;10:591-596. doi: 10.2147/OTT.S124097. eCollection 2017.
Ramanathan RK, Goldstein D, Korn RL, Arena F, Moore M, Siena S, Teixeira L, Tabernero J, Van Laethem JL, Liu H, McGovern D, Lu B, Von Hoff DD. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Ann Oncol. 2016 Apr;27(4):648-53. doi: 10.1093/annonc/mdw020. Epub 2016 Jan 22.
Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006. Epub 2016 Jan 22.
Goldstein D, Von Hoff DD, Moore M, Greeno E, Tortora G, Ramanathan RK, Macarulla T, Liu H, Pilot R, Ferrara S, Lu B. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). Eur J Cancer. 2016 Jan;52:85-91. doi: 10.1016/j.ejca.2015.10.017. Epub 2015 Dec 1.
Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardiere C, Hammel P, Lecomte T, Dreanic J, Coriat R, Bachet JB, Dubreuil O, Marthey L, Dahan L, Tchoundjeu B, Locher C, Lepere C, Bonnetain F, Taieb J. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015 Sep 29;113(7):989-95. doi: 10.1038/bjc.2015.328. Epub 2015 Sep 15.
Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015 Jan 31;107(2):dju413. doi: 10.1093/jnci/dju413. Print 2015 Feb.
Vogel A, Pelzer U, Salah-Eddin AB, Koster W. First-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice. In Vivo. 2014 Nov-Dec;28(6):1135-40.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.
Von Hoff DD, Cridebring D, Tian OY, Han H, Bhore R, Franco T, Ondovik MS, Louis CU. Analysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer. Oncologist. 2021 Apr;26(4):e704-e709. doi: 10.1002/onco.13645. Epub 2021 Jan 11.
McCleary-Wheeler AL, McWilliams R, Fernandez-Zapico ME. Aberrant signaling pathways in pancreatic cancer: a two compartment view. Mol Carcinog. 2012 Jan;51(1):25-39. doi: 10.1002/mc.20827.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA046
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.